Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
05/2003
05/02/2003EP1306377A2 Pyridyl-oxazoles and their use as cytokines inhibitors
05/02/2003EP1306373A1 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient
05/02/2003EP1306368A2 3,4-dihydro-1H-naphtalene derivatives as a highly selective cyclooxygenase-2 inhibitor
05/02/2003EP1306367A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
05/02/2003EP1305636A2 Screening method
05/02/2003EP1305635A2 Methods to identify compounds that modulate rage
05/02/2003EP1305435A1 Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
05/02/2003EP1305434A2 A human disintegrin protein
05/02/2003EP1305404A2 Protein phosphatases
05/02/2003EP1305340A2 Sequences for integrin alpha-8
05/02/2003EP1305334A1 Urocortin proteins and uses thereof
05/02/2003EP1305330A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
05/02/2003EP1305329A1 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl)oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
05/02/2003EP1305322A2 Derivatives of branched-chain lipophilic molecules and uses thereof
05/02/2003EP1305319A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
05/02/2003EP1305316A2 Azabicyclic derivatives and their therapeutic use
05/02/2003EP1305313A1 Fused heterocyclic derivatives as phosphodiesterase inhibitors
05/02/2003EP1305306A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
05/02/2003EP1305304A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor
05/02/2003EP1305294A2 Imidazolyl derivatives
05/02/2003EP1305293A1 Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase
05/02/2003EP1305291A1 3-substituted isoquinolin-1-yl derivatives
05/02/2003EP1305285A1 N-substituted indoles useful in the treatment of diabetes
05/02/2003EP1305050A2 Improved oral dosage formulations
05/02/2003EP1305037A2 Anti-inflammatory medicament
05/02/2003EP1305024A1 Method for treating fibrotic diseases or other indications ic
05/02/2003EP1305023A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
05/02/2003EP1305008A2 Improved forms of pharmaceutically active agents and method for manufacture thereof
05/02/2003EP1305006A2 Dispersions for formulating slightly or poorly soluble active ingredients
05/02/2003EP1305004A1 Embolization using carbon coated particles
05/02/2003EP1304992A1 Topical gel delivery system
05/02/2003EP1223966B1 Use of gdnf for treating corneal defects
05/02/2003EP1221939A4 Ortho ester lipids
05/02/2003EP1200064B1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip
05/02/2003EP1070058B1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
05/02/2003EP1025082B1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments
05/02/2003EP1021171B1 Delayed total release gastrointestinal drug delivery system
05/02/2003EP0948544B1 Monovalent antibody fragments
05/02/2003EP0929578B1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/02/2003EP0802983B1 Expression of urokinase plasminogen activator inhibitors
05/02/2003EP0772592B1 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS
05/02/2003EP0724387B1 Angiotension ii receptor antagonists for the treatment of chronic anti-inflammatory diseases
05/02/2003EP0715519B1 Immunomodulatory, anti-inflammatory, and anti-proliferative compounds: 5,6-dideoxy, 5-amino derivatives of idose and 6-deoxy, 6-amino derivatives of glucose
05/02/2003CA2411015A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/02/2003CA2411011A1 5-heteroatom-substituted pyrazoles
05/02/2003CA2410466A1 Hydrazinyl and nitrogen oxide pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035835A2 Glycoprotein compositions
05/01/2003WO2003035684A1 Ee3-protein family and corresponding dna sequences
05/01/2003WO2003035679A2 Molecules
05/01/2003WO2003035668A2 Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
05/01/2003WO2003035654A1 Phosphonic acid compounds as inhibitors of serine proteases
05/01/2003WO2003035650A1 Entry inhibitor
05/01/2003WO2003035644A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003WO2003035638A1 4-imidazolin-2-one compounds
05/01/2003WO2003035627A1 Piperazine derivatives with ccr1 receptor antagonist activity
05/01/2003WO2003035626A2 Azole derivatives and pharmaceutical compositions containing them
05/01/2003WO2003035625A1 Substituted indazole compounds for the treatment of inflammation
05/01/2003WO2003035237A2 Compounds for use as surfactants
05/01/2003WO2003035081A1 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
05/01/2003WO2003035079A1 A combination product comprising melagatran and dexamethasone
05/01/2003WO2003035075A1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
05/01/2003WO2003035068A1 Macrolides containing pharmaceutical compositions
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035064A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
05/01/2003WO2003035056A1 Combination of liponic acid and glutamine in food and pharmaceutical products
05/01/2003WO2003035042A1 Use of a multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia
05/01/2003WO2003035037A1 Solid pharmaceutical formulation for a piperazine urea derivative
05/01/2003WO2003035007A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
05/01/2003WO2003035005A2 Heteroindanes: a new class of potent cannabimimetic ligands
05/01/2003WO2003035000A2 Method for treating non-neuropathic pain
05/01/2003WO2003034995A2 Integrin targeting compounds
05/01/2003WO2003034991A2 Taste masking spill-resistant formulation
05/01/2003WO2003008412A3 Hetero-bicyclic crf antagonists
05/01/2003WO2003002109A8 Use of tyrosine kinase inhibitors for treating autoimmune diseases
05/01/2003WO2002100351A3 A method for treating inflammatory diseases by administering a ppar-delta agonist
05/01/2003WO2002099388A3 Benzodiazepine bradykinin antagonists
05/01/2003WO2002096435A3 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
05/01/2003WO2002094215A3 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
05/01/2003WO2002090553A3 Recombinant fusion proteins and the trimers thereof
05/01/2003WO2002090352A3 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
05/01/2003WO2002076483A3 Bacteriophage preparation
05/01/2003WO2002076438A3 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
05/01/2003WO2002074292A3 Hormone replacement therapy
05/01/2003WO2002048148A3 Pyrazolopyridine derivatives
05/01/2003WO2002046158A9 Piperidine/piperazine-type inhibitors of p38 kinase
05/01/2003WO2002030409A9 Methods for the treatment of a traumatic central nervous system injury
05/01/2003WO2002022851A3 Novel tumor-associated marker
05/01/2003WO2002005834A3 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions
05/01/2003WO2002005830A3 Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof
05/01/2003US20030083739 For treating vascular in-stent restenosis; drug delivery
05/01/2003US20030083504 N- (4-carbamimidoyl-phenyl) -glycine derivatives
05/01/2003US20030083500 Imidazonaphthyridines
05/01/2003US20030083472 Cell surface molecule mediating cell adhesion and signal transmission
05/01/2003US20030083465 Protein for use in treatment and prevention of angiogenesis
05/01/2003US20030083385 Such as 1-(5-(2-(5-chloro-2-methoxybenzamido)ethyl)-2-(2-methoxyethoxy) -(phenylsulfonyl)-3-methylthiourea; treating cardiovascular disorders
05/01/2003US20030083379 Rapidly absorbed liquid compositions
05/01/2003US20030083363 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
05/01/2003US20030083347 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/01/2003US20030083345 Method of treatment and/or prevention of brain, spinal or nerve injury
1 ... 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 ... 1272